Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccine candidates in STD.

Mark A Fletcher1

  • 1Medical Affairs Department, Aventis Pasteur, 2, avenue Pont Pasteur, F-69367 Lyon Cedex 07, France. FletchM@wyeth.com

International Journal of STD & AIDS
|January 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Respiratory Syncytial Virus Infection in Older Adults in Asia: A Modified Delphi Expert Consensus on Surveillance, Diagnosis, and Prevention.

Pulmonary therapy·2025
Same author

Frequency and Mortality of Adult Meningitis, Pneumonia, or Bacteremia in Colombia from 2015 to 2022: A Retrospective Database Study in a Health Maintenance Organization.

Journal of health economics and outcomes research·2025
Same author

Recommendations for pneumococcal vaccination of at-risk children: a global overview (2022-2024).

Vaccine·2025
Same author

Cost-effectiveness of a 13-valent pneumococcal conjugate vaccine compared with currently available pneumococcal conjugate vaccines in Indian children.

IJID regions·2025
Same author

Lyme Borreliosis and Tick Surveillance Epidemiology in the WHO Regions of the Americas, Eastern Mediterranean, Europe, South-East Asia, and Western Pacific: A Systematic Literature Review (2005-2022) Beyond North America (Canada, United States of America), European Union Countries, and China.

Vector borne and zoonotic diseases (Larchmont, N.Y.)·2025
Same author

Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same journal

Switching to long-acting anti-retroviral therapy with no baseline resistance data: is there value in proviral DNA sequencing? A single-centre pilot study.

International journal of STD & AIDS·2026
Same journal

A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections.

International journal of STD & AIDS·2026
Same journal

Long-acting injectable cabotegravir/rilpivirine in a pregnant woman living with HIV with hyperemesis gravidarum:a case report and review of literature.

International journal of STD & AIDS·2026
Same journal

BASHH best practice statement on the management of testosterone-associated vulvovaginitis.

International journal of STD & AIDS·2026
Same journal

Diagnostic accuracy of the Xpert HPV assay in women starting antiretroviral treatment in South Africa.

International journal of STD & AIDS·2026
Same journal

Perceptions of acceptability and preferences surrounding a hypothetical syphilis vaccine in Lima, Peru.

International journal of STD & AIDS·2026
See all related articles

Developing vaccines for sexually transmitted diseases (STDs) faces challenges unlike respiratory vaccines. Overcoming scientific and manufacturing hurdles is key to creating effective STD vaccines for prevention and treatment.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Sexually transmitted diseases (STDs) infect genitourinary mucosal surfaces.
  • STD vaccine research lags behind respiratory tract pathogen vaccine development.
  • Existing respiratory vaccines include live-attenuated viruses and subunit/protein approaches.

Purpose of the Study:

  • To review the challenges and progress in developing vaccines for sexually transmitted diseases.
  • To identify key scientific, manufacturing, and public health considerations for STD vaccine development.
  • To explore potential future strategies for STD vaccine design and administration.

Main Methods:

  • Literature review of current STD vaccine research and challenges.
  • Analysis of scientific hurdles such as antigen selection, attenuation, immunopathology, immunogenicity, and antigenic heterogeneity.

Related Experiment Videos

  • Examination of manufacturing and public health aspects including delivery systems, formulation, and marketing.

    • Main Results:

    • Significant scientific obstacles impede STD vaccine development, including issues with human herpes simplex virus type 2 attenuation, Chlamydia trachomatis immunopathology, Treponema pallidum immunogenicity, and Neisseria gonorrhoeae antigenic variation.
    • Ongoing efforts utilize protein antigens from various pathogens like Haemophilus ducreyi, N. gonorrhoeae, C. trachomatis, human herpes simplex virus type 2, and human papilloma virus.
    • Potential future STD vaccines may involve live-attenuated viruses, subunit proteins or inactivated whole organisms with adjuvants, or DNA plasmids.

    Conclusions:

    • Advancing STD vaccine research requires addressing complex scientific, manufacturing, and public health challenges.
    • Despite difficulties, progress is being made using various antigen types and innovative approaches.
    • Future STD vaccines are likely to employ strategies such as live-attenuated viruses, subunit/inactivated vaccines with adjuvants, or DNA-based vaccines.